Versiti Indiana Inc is a 501(c)(3) organization based in Indianapolis, Indiana, registered in 1954, with $93,681,273 in FY2024 revenue. CharityIndex grades it A, and it directs about 86% of spending to programs.
Revenue (FY2024)
$93.7M
▲ 7.7% vs prior year
Health median: $840K
Expenses (FY2024)
$93.6M
Net assets
$35.3M
Employees
877
Measures how much of every dollar spent actually reaches programs, plus what it costs to raise $100 of donations. The worse of the two measures sets the letter (85%+ to programs is an A; under $15 to raise $100 is an A), averaged over the three most recent filings. For Versiti Indiana Inc: 86% to programs earns a A on this criterion. See the exact thresholds →
Measures whether the organization is built to last: how many months its reserves would cover expenses (3+ months earns an A-range score, but hoarding 5+ years of budget is capped) and whether it runs a surplus or a deficit. For Versiti Indiana Inc: 5 mo reserves · +0% margin earns a A on this criterion. See the exact thresholds →
Checks how the organization is run, from its own Form 990: an independent board majority, a board of five or more, conflict-of-interest, whistleblower and document-retention policies, and independently audited financials. The share of disclosed checks that pass sets the letter. For Versiti Indiana Inc: 6 of 6 checks met earns a A+ on this criterion. See the exact thresholds →
Counts five disclosure signals: a recent filing, a mission statement, program descriptions, a listed website, and the full expense breakdown. More disclosure, better letter. For Versiti Indiana Inc: 5 of 5 disclosure signals earns a A+ on this criterion. See the exact thresholds →
Show this grade on your website
A live seal — it updates automatically when the grade changes and links donors to this verified profile.
(see schedule o)
The versiti donor testing laboratory (dtl) provides infectious disease testing to determine donor suitability and product safety for organs, tissues, hematopoietic stem cells, and cord blood. the dtl offers nucleic acid testing, antibody screening, and confirmatory testing for many different disease states. in 2024, the dtl conducted 8,321,196 donor tests, ensuring the safety of its donated biological products. as part of versiti's mission to maintain the safest possible blood supply, donor testing operations conduct mandatory screening for transfusion-transmissible infections as required by fda regulations. the dtl utilizes state-of-the-art nucleic acid testing (nat) technology and serological methods to detect infectious agents. versiti's dtl supports blood collection activities (continued in schedule o) across versiti's entire geographic footprint while maintaining rigorous quality standards and regulatory compliance. versiti's donor testing services strengthen the national blood supply infrastructure. by ensuring comprehensive donor screening, versiti protects patients who depend on safe blood transfusions, strengthens the national blood supply, and supports the broader public health mission of maintaining confidence in a high-quality blood supply.
Revenue grew from $61.5M (FY2013) to $93.7M (FY2024) across 10 reported years.
Financial snapshot
Operating margin
0.1%
Revenue exceeded expenses in the latest fiscal year.
Total assets
$59.4M
Total liabilities
$24.1M
Net assets
$35.3M
Salaries & benefits
$36.8M
39% of expenses
Board members
18
17 independent
| Fiscal year | Revenue | Expenses | Net assets | Total assets | Form |
|---|---|---|---|---|---|
| 2024 | $93,681,273▲7.7% | $93,568,944▲5.5% | $35,343,263▲1.9% | $59,403,654▲29.4% | 990 |
| 2023 | $87,010,628▲5.0% | $88,681,219▲2.4% | $34,674,465▼4.4% | $45,922,381▲2.4% | 990 |
| 2022 | $82,888,897▼9.5% | $86,577,919▼5.8% | $36,288,095▼16.1% | $44,844,226▼14.5% | 990 |
| 2021 | $91,566,371▲5.5% | $91,902,492▲9.9% | $43,229,461▲1.2% | $52,476,329▲0.1% | 990 |
| 2020 | $86,812,127▲14.6% | $83,596,079▲9.8% | $42,697,968▲11.7% | $52,408,972▲15.2% | 990 |
| 2019 | $75,734,257▲11.5% | $76,120,899▲13.4% | $38,232,326▲8.9% | $45,507,285▲5.4% | 990 |
| 2017 | $67,899,503▲10.1% | $67,115,565▲12.5% | $35,120,102▲6.2% | $43,159,200▲8.4% | 990 |
| 2016 | $61,644,040▲20.0% | $59,655,243▲11.8% | $33,069,828▲6.6% | $39,806,696▲13.2% | 990 |
| 2015 | $51,374,471▼16.5% | $53,378,537▼9.8% | $31,018,977▼17.3% | $35,154,160▼17.3% | 990 |
| 2013 | $61,491,024 | $59,159,261▼7.8% | $37,489,506▲11.4% | $42,497,909▲14.2% | 990 |
| 2012 | — | $64,165,070▲3.0% | $33,660,268▲1.5% | $37,201,804▼2.7% | 990 |
| 2011 | — | $62,303,751▲7.8% | $33,151,121▲8.0% | $38,241,358▲10.9% | 990 |
| 2010 | — | $57,803,465▼2.5% | $30,697,238▲14.2% | $34,467,488▲4.7% | 990 |
| 2009 | — | $59,272,424 | $26,886,224 | $32,907,412 | 990 |
Original Form 990 PDFs (the Form column) are served by ProPublica Nonprofit Explorer, as filed with the IRS. Create a free account to download the CSV report.
Highest-paid: Julie Cruz Md — $376,721 (0.40% of total expenses)
| Name | Title | Hours/week | Compensation |
|---|---|---|---|
| Julie Cruz Md | Sr Medical Director | 55 | $376,721 |
| Chris Miskel | President & Ceo | 10 | $308,294 |
| Lora Poore | Sr Strategist Innovation | 55 | $275,713 |
| Penny Schroeder | Avp & Sr Dr Donor Testing Labs | 55 | $233,482 |
| Jeffrey Fuller | Sr Dr Enterprise Architecture | 55 | $163,871 |
| Bart Reuter | Evp & General Counsel | 10 | $163,705 |
| Brian Bautista | Evp & Chief Operating Officer | 10 | $154,426 |
| Anthony Watkins | Evp&cfo-thru 3/24;bus Dev-as of 3/24 | 10 | $142,255 |
| Matt Cooper | Sr Mgr Digital Marketing | 55 | $133,370 |
| Bradley Pietz | Evp & Chief Laboratory Officer | 10 | $114,176 |
| James Weidner | Evp & Chief Hr Officer | 10 | $108,605 |
| Lynne Briggs | Vp & Chief Information Officer | 10 | $91,555 |
| Derek Tyus | Evp & Chief Financial Off. - As 3/24 | 10 | $85,939 |
| Dan Waxman Md | Vp Transfusion Medicine | 10 | $83,730 |
| Gitesh Dubal | Evp & Chief Mktg. Off. - Thru 4/24 | 10 | $77,341 |
| Jessica Drouillard | Vp & Chief Quality Officer | 10 | $52,447 |
| Gretchen Jameson | Evp & Chief Mktg. Off. - As of 4/24 | 10 | $41,879 |
| Barbara Bryant | Evp & Chief Med. Off. - Thru 8/24 | 1 | — |
| Cecelia Gore | Board Member | 1 | — |
| Coreen Dicus-johnson Jd | Secretary | 1 | — |
| Contractor | Services | Paid |
|---|---|---|
| Actalent Scientific LLC | Employment Agency | $546,711 |
| Invita Healthcare Technologies | Software Support | $341,777 |
| Gpi USA Inc | Software Support | $322,373 |
| Keen Security and Investigative Services | Security Services | $263,520 |
| Creative Testing Solutions | Testing Services | $226,903 |
5 grants to Versiti Indiana Inc totaling $206K, reported by foundations on their Schedule I filings.
| Grantmaker | Purpose | Year | Amount |
|---|---|---|---|
| National Christian Charitable Foundation | Support | 2017 | $5,000 |
| National Christian Charitable Foundation | Growth | 2017 | $1,000 |
| Versiti Blood Health Inc | Scholarship fund | 2015 | $128,000 |
| Versiti Michigan Inc | Scholarships | 2015 | $36,000 |
| Versiti Illinois Inc | Scholarships | 2015 | $36,000 |
1 grant totaling $9,500 in FY2023. All grants made by Versiti Indiana Inc →
| Recipient | Purpose | Amount |
|---|---|---|
| Ohio High School Athletic Association | General support | $9,500 |
Explore more
Data for Versiti Indiana Inc (EIN 35-0991629) comes from the IRS Business Master File and e-filed Form 990 returns, via CharityIndex. Figures reflect what the organization reported to the IRS for each fiscal year.